MX2019004222A - Protective effect of dmpc, dmpg, dmpc/dmpg, egpg, lysopg and lysopc against drugs that cause channelopathies. - Google Patents
Protective effect of dmpc, dmpg, dmpc/dmpg, egpg, lysopg and lysopc against drugs that cause channelopathies.Info
- Publication number
- MX2019004222A MX2019004222A MX2019004222A MX2019004222A MX2019004222A MX 2019004222 A MX2019004222 A MX 2019004222A MX 2019004222 A MX2019004222 A MX 2019004222A MX 2019004222 A MX2019004222 A MX 2019004222A MX 2019004222 A MX2019004222 A MX 2019004222A
- Authority
- MX
- Mexico
- Prior art keywords
- dmpg
- dmpc
- egpg
- lysopg
- channelopathies
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention includes compositions and methods for preventing one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns caused by an active agent or a drug in a human or animal subject comprising: an amount of a phosphatidylglycerol adapted for oral administration effective to reduce or prevent one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns caused by the active agent or drug, and one or more organoleptic, thixotropic, or both organoleptic and thixotropic agents.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/297,901 US10449193B2 (en) | 2011-06-03 | 2016-10-19 | Protective effect of DMPC, DMPG, DMPC/DMPG, lysoPG and lysoPC against drugs that cause channelopathies |
PCT/US2017/057446 WO2018075801A1 (en) | 2016-10-19 | 2017-10-19 | Protective effect of dmpc, dmpg, dmpc/dmpg, egpg, lysopg and lysopc against drugs that cause channelopathies |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019004222A true MX2019004222A (en) | 2019-06-10 |
Family
ID=62019674
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019004222A MX2019004222A (en) | 2016-10-19 | 2017-10-19 | Protective effect of dmpc, dmpg, dmpc/dmpg, egpg, lysopg and lysopc against drugs that cause channelopathies. |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP3528848A4 (en) |
JP (1) | JP2019531309A (en) |
KR (1) | KR20190042775A (en) |
CN (2) | CN109843331A (en) |
AU (2) | AU2017345473A1 (en) |
CA (1) | CA3039596C (en) |
MX (1) | MX2019004222A (en) |
WO (1) | WO2018075801A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2018209164B2 (en) | 2017-01-17 | 2021-11-04 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
EP3697386B1 (en) * | 2017-10-19 | 2023-07-26 | Signpath Pharma, Inc. | Liquid compositions for peroral use comprising phosphatidylglycerol derivatives and thixotropic excipients for treating cardiac channelopathies caused by pharmacological agents |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8618847D0 (en) * | 1986-08-01 | 1986-09-10 | Smith Kline French Lab | Pharmaceutical formulations |
GB9224855D0 (en) * | 1992-11-27 | 1993-01-13 | Smithkline Beecham Plc | Pharmaceutical compositions |
UA80682C2 (en) * | 2001-08-06 | 2007-10-25 | Pharmacia Corp | Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition |
US20050233970A1 (en) * | 2004-03-23 | 2005-10-20 | Praecis Pharmaceuticals, Inc. | Methods for treating long QT syndrome |
WO2008093848A1 (en) * | 2007-02-02 | 2008-08-07 | Sunstar Inc. | Composition for decreasing inflammation marker comprising phosphatidylcholine |
JP5638204B2 (en) * | 2009-05-29 | 2014-12-10 | 国立大学法人 岡山大学 | Liposome preparation for oral administration and production method thereof |
WO2012094033A1 (en) * | 2011-01-05 | 2012-07-12 | Livon Laboratories | Methods of making liposomes, liposome compositions made by the methods, and methods of using the same |
CA2836904C (en) * | 2011-06-03 | 2019-09-24 | Signpath Pharma Inc. | Liposomal mitigation of drug-induced long qt syndrome and potassium delayed-rectifier current |
WO2013121300A2 (en) * | 2012-02-16 | 2013-08-22 | Vascular Biogenics Ltd. | Methods for treating psoriasis and vascular inflammation |
CA2882978A1 (en) * | 2012-08-31 | 2014-03-06 | University Of North Texas Health Science Center | Curcumin-er, a liposomal-plga sustained release nanocurcumin for minimizing qt prolongation for cancer therapy |
JP2017516813A (en) * | 2014-06-03 | 2017-06-22 | サインパス ファルマ, インク.Signpath Pharma, Inc. | Protective effects of DMPC, DMPG, DMPC / DMPG, EGPG, LYSOPG and LYSOPC against drugs that cause channel disease |
-
2017
- 2017-10-19 MX MX2019004222A patent/MX2019004222A/en unknown
- 2017-10-19 WO PCT/US2017/057446 patent/WO2018075801A1/en unknown
- 2017-10-19 EP EP17861307.1A patent/EP3528848A4/en not_active Withdrawn
- 2017-10-19 CA CA3039596A patent/CA3039596C/en active Active
- 2017-10-19 AU AU2017345473A patent/AU2017345473A1/en not_active Abandoned
- 2017-10-19 CN CN201780064810.5A patent/CN109843331A/en active Pending
- 2017-10-19 JP JP2019518559A patent/JP2019531309A/en active Pending
- 2017-10-19 CN CN202010289224.4A patent/CN111481508A/en active Pending
- 2017-10-19 KR KR1020197011064A patent/KR20190042775A/en not_active IP Right Cessation
-
2020
- 2020-11-13 AU AU2020267307A patent/AU2020267307A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN111481508A (en) | 2020-08-04 |
CN109843331A (en) | 2019-06-04 |
AU2020267307A1 (en) | 2020-12-10 |
AU2017345473A1 (en) | 2019-04-18 |
JP2019531309A (en) | 2019-10-31 |
KR20190042775A (en) | 2019-04-24 |
WO2018075801A1 (en) | 2018-04-26 |
CA3039596C (en) | 2022-04-12 |
EP3528848A1 (en) | 2019-08-28 |
CA3039596A1 (en) | 2018-04-26 |
EP3528848A4 (en) | 2020-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3207931A3 (en) | Protective effect of dmpc, dmpg, dmpc/dmpg, egpg, lysopg and lysopc against drugs that cause channelopathies | |
MX2019005141A (en) | Protective effect of dmpc, dmpg, dmpc/dmpg, lysopg and lysopc against drugs that cause channelopathies. | |
PH12019502058A1 (en) | Farnesoid x receptor agonists and uses thereof | |
MX2016000364A (en) | Methods for treating or preventing ophthalmological conditions. | |
MX2018003388A (en) | Farnesoid x receptor agonists and uses thereof. | |
MX2017014338A (en) | Targeted selection of patients for treatment with cortistatin derivatives. | |
JOP20190281A1 (en) | N2,n4-diphenylpyrimidin-2,4-diamine derivative, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of cancer | |
EA201691454A1 (en) | COMPOSITIONS OF PRIDOPIDININE MODIFIED SHIPPING | |
PH12018502109A1 (en) | Medicine obtained by combining fxr agonist and arb | |
MX2016010179A (en) | Donepezil compositions and method of treating alzheimer's disease. | |
PH12017502376A1 (en) | Oral solid formulation containing irinotecan and method of preparing the same | |
CO2017003263A2 (en) | Pharmaceutical composition based on anamorelin having activity on cachexia caused by cancer | |
MX2022011372A (en) | Zinc-î³-pga compositions and methods for treating cancer. | |
PH12016502233A1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
MX2019001467A (en) | Combination of glucagon receptor antagonists and pi3k pathway inhibitors for the treatment of cancer. | |
IL274456A (en) | Inhibitor of the expression of cancer-promoting factors, screening method for active ingredient thereof, expression cassette useful in said method, diagnostic drug, and diagnostic method | |
MX2019004222A (en) | Protective effect of dmpc, dmpg, dmpc/dmpg, egpg, lysopg and lysopc against drugs that cause channelopathies. | |
MX2023006235A (en) | Compositions for drug delivery and methods of use thereof. | |
NZ602807A (en) | 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one and an mtor inhibitor | |
MX2017014776A (en) | Pharmaceutical combination of everolimus with dactolisib. | |
MX2023007136A (en) | Protective effect of dmpc, dmpg, dmpc/dmpg, lysopg and lysopc against drugs that cause channelopathies. | |
MX2020010243A (en) | Oral compositions and methods for animals. | |
ZA202104167B (en) | Compounds for use in the treatment of parkinson's disease | |
RU2014107146A (en) | METHOD FOR PREVENTING A CARCINOGENIC EFFECT OF DIETHYLNITROSAMINE IN EXPERIMENTAL ANIMALS | |
MX2019013912A (en) | Combination of a 5-ht6 receptor antagonist and an acetylcholinesterase inhibitor for use in the treatment of alzheimer's disease in a patient subpopulation carrying apoe4 alleles. |